The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy.
Vincent M. Chung
No relevant relationships to disclose
Shannon McDonough
No relevant relationships to disclose
Philip Agop Philip
No relevant relationships to disclose
Dana Backlund Cardin
No relevant relationships to disclose
Andrew M. Lowy
No relevant relationships to disclose
Jacqueline K. Benedetti
No relevant relationships to disclose
Charles Davic Blanke
No relevant relationships to disclose